XNAS · Healthcare · Biotechnology
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | Q1 2026 | -0.16 | -0.15 | +8.12% | $0 | ✅ Beat | +2.67% | -2.40% | — |
| 2026-02-27 | Q4 2025 | -0.34 | -0.37 | -8.82% | $0 | ❌ Miss | +3.83% | +4.74% | -9.48% |
| 2025-11-07 |
| Q3 2025 |
| -0.37 |
| -0.36 |
| +2.70% |
| $0 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-12 | Q2 2025 | -0.37 | -0.44 | -18.92% | $0 | ❌ Miss | -3.19% | +44.63% | +91.84% |
| 2025-03-06 | Q4 2024 | -0.39 | -0.44 | -12.82% | $0 | ❌ Miss | -19.08% | -36.53% | -59.14% |
| 2024-11-07 | Q3 2024 | -0.78 | -0.45 | +42.31% | $0 | ✅ Beat | -3.97% | -11.92% | +13.91% |
| 2024-03-07 | Q4 2023 | -0.86 | -0.79 | +8.14% | $0 | ✅ Beat | — | — | — |
| 2023-11-13 | Q3 2023 | -0.87 | -1.07 | -22.99% | $0 | ❌ Miss | +4.75% | +16.25% | +57.77% |
Showing last 8 quarters.